EP Patent

EP4072542A1 — Liquid tasimelteon formulations and methods of use thereof

Assigned to Vanda Pharmaceuticals Inc · Expires 2022-10-19 · 4y expired

What this patent protects

Liquid suspensions of tasimelteon and methods for their use.

USPTO Abstract

Liquid suspensions of tasimelteon and methods for their use.

Drugs covered by this patent

Patent Metadata

Patent number: EP4072542A1
Jurisdiction: EP
Classification: —
Expires: 2022-10-19
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.